Danielle Bucco


Standard of Care Continues to Shift in RCC

May 11th 2018

Toni K. Choueiri, MD, discusses recent advancements and shares his insight on the future treatment landscape of patients with kidney cancer.

Frontline Treatment in Ovarian Cancer Could Undergo Transformation

May 10th 2018

Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.

Hamlin Discusses Practice-Changing Data in Lymphoma

April 25th 2018

Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.

Following FDA Approvals, CML Pipeline Has Challenges

April 25th 2018

Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.

CAR T-Cell Therapy Starts to Enter MCL Space

April 23rd 2018

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.

Expert Highlights Advances Across Lymphoma Subtypes

April 23rd 2018

Alison J. Moskowitz, MD, discusses the latest treatment advances across subtypes of lymphoma.

Role of PARP Inhibitors in Breast Cancer Continues to Be Refined

April 20th 2018

Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

Diet Linked With Tumor Aggressiveness in Endometrial Cancer

April 19th 2018

Lindsay West, MD, discusses the relationship between low-fat or high-fat diets and endometrial cancer and how these can be investigated further.

PV Treatment Landscape Balancing Effective Regimens With QOL Challenges

April 18th 2018

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

Giant of Cancer Care Shares Insights on Adjuvant Therapy in Melanoma

April 18th 2018

Adjuvant treatment of patients with intermediate- and high-risk melanoma has changed drastically in the past decade, according to John M. Kirkwood, MD.

Developments Expanding Frontline NSCLC Treatment

April 13th 2018

Thomas E. Stinchcombe, MD, discussea existing and emerging first-line regimens coming through the pipeline for the treatment of patients with non–small cell lung cancer.

Treatment Developments Shaking Up Landscape for Nonmetastatic CRPC

April 13th 2018

Mark J. Mann, MD, discusses the developing treatment landscape for patients with nonmetastatic CRPC.

Ongoing Trial to Determine Role of Degarelix in Lowering Cardiovascular AEs in Prostate Cancer

April 12th 2018

The ongoing phase IIIb PRONOUNCE trial is seeking to determine if the gonadotropin-releasing hormone receptor antagonist degarelix (Firmagon) is more likely to reduce cardiovascular events in patients with advanced prostate cancer and CVD versus the GnRH agonist receptor leuprolide.

New Agents on Horizon for HER2-Positive Breast Cancer

April 12th 2018

There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.

Expert Shares Treatment Updates for Neuroendocrine Tumors

April 10th 2018

The incidence of neuroendocrine tumors has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies.

Pegram Highlights Progress in HER2+ Breast Cancer

April 9th 2018

Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.

Treatments Emerging to Combat Endocrine Resistance in ER+ Breast Cancer

April 6th 2018

Heather Han, MD, discusses emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.

Expert Reviews CLL Advances Presented at ASH

April 5th 2018

Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.

Bekaii-Saab Highlights Emerging Agents in Pancreatic Cancer Pipeline

March 30th 2018

Tanios Bekaii-Saab, MD, discusses emerging treatments offering hope to patients with pancreatic cancer.

Precision Medicine Impact Grows in GI Cancer Paradigm

March 30th 2018

Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.